社区

Ah, yes. Reports of gloom and doom. Despair. Pain! Slaughter!! They say, "No one will travel in the future economy!" Yet, ABNB posts its best quarter ever and still expects double digit growth ...so I want to thank Mr. Market for his pessimism. More pain may come, but I bought today.$Airbnb, Inc.(ABNB)$

With earnings coming out in 5 weeks, I imagine a lot of buying is taking place. Get in now because Facebook will be up 35% next year.$Meta Platforms, Inc.(FB)$

Hong Kong’s underperforming stocks will likely rebound in 2022, with a border reopening with mainland China to benefit (((gaming))))and retail shares while rising yields hold banks up $TENCENT(00700)$

The thing about GRAB that really sucks is that the premium in the call options have dried up. Non existent. $Grab Holdings(GRAB)$

Absolutely no point in holding this. There’s a reason it’s called a “meme trade” lmfao. I love watching longs painfully convince themselves that this stock holds value. Good luck with ur losses.$AMC Entertainment(AMC)$

Once upon a time Apple and Disney had almost identical share prices. Now, Apple is ahead by nearly $25 per......oh, and Apple split into 4 shares for every 1 since the start of this story...$Walt Disney(DIS)$ $Apple(AAPL)$

UBS analyst Colin Bristow placed a buy rating on Pfizer's stock and boosted his share price forecast from $52 to $60. Bristow estimates that the pharmaceutical titan will earn at least $14 billion in sales from its new oral antiviral treatment, Paxlovid. The pill has been shown to reduce the risk of hospitalization or death in high-risk patients with COVID-19 by nearly 90% in clinical trials. All told, Bristow sees Pfizer earning as much as $50 billion in sales from COVID-19 vaccines and treatments in 2022. investors applauded Pfizer's acquisition of Arena Pharmaceuticals (NASDAQ:ARNA). Mizuho analyst Vamil Divan lifted his price target on Pfizer's stock from $44 to $56 after news of the deal broke. Divan views the purchase of Arena as an intelligent way for Pfizer to diversify its produc

iPhone demand outstripping supply, Glasses set for 2022 debut, maintained Outperform. Apple store checks, supply chain data, and iPhone order delays all confirm my bullish view that currently demand is outstripping supply for iPhones 13 by roughly 10 million units globally. iPhone 13 checks continue to be much stronger than expected, with belief that Apple is now on pace to sell north of 40 million iPhones during the holiday season despite the chip shortage headwinds.$Apple(AAPL)$

Folks, we are getting a gift at these levels , buy and double your profits in 6 months. Amazing growth in this company and it will continue throughout 2022. Higher interest rates will not affect this company, it will only help as consumers will need the best rates and banks will need better data on providing loans.$Upstart Holdings, Inc.(UPST)$

The YouTube dispute was a big overhang on the stock. Resolution helps in many ways. Now, time to resume the journey. Better days ahead!$Roku Inc(ROKU)$